ELEVATION ONCOLOGY INC (ELEV) Stock Analyst Ratings
USA - NASDAQ:ELEV - US28623U1016 - Common Stock
0.365 USD
-0.01 (-2.12%)
0.377 USD
+0.01 (+3.29%)
ChartMill assigns a Buy % Consensus number of 73% to ELEV. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 1.52. This target is 317.31% above the current price.
ELEV was analyzed by 14 analysts. The buy percentage consensus is at 73. So analysts seem to be have mildly positive about ELEV.
In the previous month the buy percentage consensus was at a similar level.
ELEV was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-06-10 | JMP Securities | Reiterate | Market Perform -> Market Perform |
| 2025-06-10 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-06-09 | William Blair | Downgrade | Outperform -> Market Perform |
| 2025-03-24 | Stephens & Co. | Downgrade | Overweight -> Equal-Weight |
| 2025-03-21 | Citizens Capital Markets | Downgrade | Market Outperform -> Market Perform |
| 2025-03-21 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2025-03-21 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2025-03-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-10 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2025-03-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-07 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-01-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-03 | William Blair | Initiate | Outperform |
| 2024-12-19 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-12-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-06 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2024-08-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-15 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-06-28 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-05-31 | Piper Sandler | Initiate | Overweight |
| 2024-05-14 | Stephens & Co. | Initiate | Overweight |
| 2024-05-03 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-04-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-07 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-03-07 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-03-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-01 | JMP Securities | Initiate | Market Outperform |
| 2024-02-20 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-06 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-09-29 | HC Wainwright & Co. | Initiate | Buy |
ELEVATION ONCOLOGY INC / ELEV FAQ
What do analysts expect the price target to be for ELEVATION ONCOLOGY INC (ELEV)?
14 analysts have analysed ELEV and the average price target is 1.52 USD. This implies a price increase of 317.31% is expected in the next year compared to the current price of 0.365.
Can you provide the consensus rating for ELEVATION ONCOLOGY INC stock?
The consensus rating for ELEVATION ONCOLOGY INC (ELEV) is 72.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.